



## Expanded Scope of Pharmacy Practice in New Brunswick Hospitals

Luc Jalbert, Vitalité Health Network Douglas Doucette, Horizon Health Network

NB Pharmacy Conference – CSHP-NB Branch June 10, 2017

# Speakers' Disclosures

### Luc Jalbert

• Nothing to declare

### **Douglas Doucette**

Nothing to declare



# Objectives

In this session, we will:

- Summarize key "pillars of evidence" for benefit of pharmacist services to patient outcomes;
- Illustrate examples of how Pharmacy Services in NB Regional Health Authorities are working in or towards expanded scope of practice (ESoP), and
- Describe next steps to lead NB hospital pharmacists to work at full scope of practice (SoP).

# **Old and Current Practices**

- In place well before the Pharmacy Act was amended
  - Disparate
  - Not same level of implication

- Examples
  - Aminoglycosides dosing (lab testing/prescriptions)
  - Drug doses/interval adjustments (renal impairment)
  - Clinical pharmacist /physician « collaboration »

# « New » Pharmacy Act

• 2008

Expanded Scope of Practice (ESoP)

- Introduced pharmacist prescribing
  - Medications
  - Clinical tests
- Collaborative practice agreements

# But... There was a dark cloud



# **Regulations to NB RHA Act**

- Did not provide the authority where a pharmacist could be a prescriber
- After legal counseling, the <u>RHA Act</u> has precedence over any other private Act
- Dept of Health asked us to continue practicing like we were; but no more developing under the Pharmacy Act
  - Until legislation was changed...

# Then, the bright sun



# Memo from Dept of Health

• Before Christmas 2016

• No need for legislation change!



 Pharmacists may work to full scope of practice under approval by each RHA

## Pillars of Evidence: Benefit of Pharmacist Services

- $\checkmark$  Bond et al.
- ✓ Kaboli et al.
- ✓ Makowsky et al.

- ✓ Gillespie et al.
- ✓ Chisholm-Burns et al.
- ✓ Cdn Consensus cpKPIs



## Summary Evidence of Benefit of Clinical Pharmacy Services

#### Kaboli et al., 2006 – Systematic Review

- 1. Attendance on patient care rounds
- 2. Patient interviews & assessments
- 3. Medication reconciliation
- 4. Discharge "counselling" (patient education on medications)
- 5. Post-discharge follow-up

#### Bond & Raehl, 2007 - Observational

- 1. Admission drug histories
- 2. Medical rounds participation
- 3. CPR team participation

#### Makowsky et al., 2010 – RCT

Overall quality score  $\rightarrow$  3- and 6-month allcause readmission (hospital or ED visit after index hospital admission)

#### Gillespie et al., 2010 – RCT

Integrated Intervention pharmaceutical care

- 1. Post-discharge hospital visits (ED + readmissions)
- 2. Emergency department visits
- 3. Drug-related readmissions

#### Chisholm-Burns et al., 2011 – SR/MA

- 1. HbA1c , LDL-c, BP
- 2. Adverse drug events

### **Consensus KPIs in the Patient Journey**



#### PATIENT ADMISSION

 Medication reconciliation at admission



#### **PATIENT STAY**

- Pharmaceutical care plan
- Resolved drug therapy problems
- Interprofessional patient care rounds
- Patient education during stay



#### PATIENT DISCHARGE

- Patient education at discharge
- Medication reconciliation at discharge

#### COMPREHENSIVE DIRECT PATIENT CARE BUNDLE

CSHP Consensus Clinical Pharmacy Key Performance Indicators Knowledge Mobilization Guide, 2015

# NB Pharmacists' WG

- Members
  - Horizon
  - Vitalité

- Focus
  - Draft P&P



# **ESoP Policies & Procedures**

- Two P&P drafted
  - Pharmacist Ordering, Administration and Interpretation of Clinical Tests
  - Pharmacist Prescribing of Medication

- Vitalité: Stakeholder consultation in progress
- Horizon: Stakeholder consultation completed

# **Clinical Tests**



- Ordering, administration & interpretation of <u>laboratory</u> and <u>diagnostic</u> investigations
   – e.g. chemistry, CBC, TDM, ECG, etc.
- New P&P will replace existing delegated functions authorizing pharmacists to order lab tests in any/all RHAs

## Clinical Tests (cont.)

- Principles for use of clinical tests by RPh:
  - Practice within scope of competence & experience
  - Clinical decision does not increase patient risk
  - Patient consent (implied or informed)
  - Appropriately document and communicate
  - Manage/monitor patient drug regimen
  - Transfer of care

## Clinical Tests (cont.)

- RPh working within Scope of Practice:
  - On NBCP Active Direct Care Client Register;
  - Registered with RHA's medical lab provider, and
  - Assess patient and/or aware of care plan, incl provide mechanism for follow up by RPh

- Pharmacists are responsible for own competence to order or administer tests, or interpret results
  - There is <u>no list</u> of tests authorized for pharmacists

## Clinical Tests (cont.)

## **Collaboration & Communication**

- Act on results, esp when out of 'normal' range
   Notify physician of clinically significant results
- Available & accessible to your team OR make alternate arrangements
  - <u>After-Hours:</u> **On-Call RPh** in lieu of prescribing RPh
  - Prescribing RPh may specify other arrangements,
     e.g. different contact person, leave chart note, etc.

# **Prescribing Medications**



Pharmacist Prescribing P&P:

• Will replace delegated functions still in place from former RHAs' MAC or P&TC

– e.g. renal dosing; TDM of vanco, AG, etc.

- Environmental scans of P&P in other Canadian hospitals
- Status quo vs new responsibilities under expanded SoP

# **Prescribing Medications**

- Principles for prescribing medication by RPh:
  - Practice within scope of competence & experience
  - Clinical decision does not increase patient risk
  - Patient consent (implied or informed)
  - Appropriately document and communicate
  - Manage/monitor patient drug regimen
  - Transfer of care

### (same as for Clinical Testing P&P)

- What?
  - Drugs in schedules I, II, III or U, or unscheduled
  - Excludes narcotic & controlled drugs
- Who & when to prescribe?
  - RPh on NBCP Active Direct Client Care Register;
  - To adapt a medication order, or
  - Providing patient care as part of collaborative care team (additional prescribing authority required).

- Continuity of Patient Care (new)
  - 1) Med rec at admission OR
  - 2) Medications taken prior to admission (not related to med rec) OR
  - 3) Med rec at discharge:
    - Based on RPh assessment or unintentional discrepancy, RPh may continue prescription meds, or continue, initiate or adjust non-prescription meds
  - 4) Reorder inpatient meds with pending stop date
    - To avoid disruption in therapy; <u>not</u> intended as routine duty
  - ✓ Write order, document rationale & follow up, as appropriate
     ✓ Notify original prescriber when clinically significant

- Increase Suitability of Medication Orders (new)
  - 1) Ambiguous or unsafe orders
    - Adapt when intent is clear; otherwise, contact prescriber
  - 2) Drug-drug interactions
    - Hold those deemed significant if unable to contact prescriber
  - 3) Discontinue non-essential supplements or nonformulary vitamins
  - ✓ Write order, document rationale & follow up, as appropriate
     ✓ Notify original prescriber when clinically significant

- Adapt dosage, formulation or regimen
  - 1) Modify dosage based on renal function
  - 2) Modify dosage based on serum levels
  - 3) IV to PO conversion of antimicrobials
    - Targeted agents as per clinical criteria (D&TC policy)
  - 4) Modify formulation
    - And/or route of admin based on patient factors
  - ✓ Write order, document rationale & follow up, as appropriate
     ✓ Notify original prescriber when clinically significant

- Collaboration & Communication
  - In addition to accurate & timely writing of medication orders, RPh will ensure plan for follow up including how to be contacted, if needed
  - <u>After-Hours:</u> On-Call RPh will be contacted with questions in lieu of prescribing RPh unless otherwise specified, e.g. care plan in chart, personal phone #, etc.
  - Expectations of medical staff\*

#### **Additional Prescribing Authority**

- Collaborative Practice Agreements
  - Allows RPh to prescribe drugs & order tests within physician team or group – seen as 'top of license'?
- Minor Ailments
  - Specific conditions & therapies as outlined in Regulations to NB Pharmacy Act (2014)
- CPA may have greater impact on care of patients in RHAs (compared to minor ailments)
- For both CPA & minor ailments, RPh must meet NBCP requirements & obtain approval of RHA pharmacy manager & clinical program

## RHA's proposed ESoP P&P

- What is <u>not</u> included:
  - Administering injections
  - Physical assessment



# **ESoP** Implementation

## Horizon Health

- As part of Pharmacy Practice Model Project
  - Define & standardize roles & responsibilities for pharmacists, technicians, assistants
  - Set priorities for patients at highest risk & with complex medication regimens
  - Strive to increase consistency & quality of pharmacy services provided to Horizon patients
  - Tied to evidence-based clinical pharmacy indicators of quality care & patient outcomes

# **ESoP** Implementation

• Vitalité Health Network

- As part of our broad Clinical Strategic Plan

- Define a standard practice model for pharmacists within all the zones
  - « Basic » clinical services
  - « Added » clinical services

# **ESoP Challenges**

- Communication
  - With patients & family



- Within pharmacy & care team (handoffs, documentation)
- Be Visible! With care team & patients, in chart, etc.
- Collaboration & Conflict
  - Focus on patient needs to build trust words matter
  - Trust will come easier for some than others
- Roles & Responsibilities
  - Anticipate 'turf' issues
  - Your 'new' roles may overlap with those of others

## ESoP Challenges (cont.)

- Dept/Site Level
  - Priorities within dept/site
  - Small vs large sites
- Training & Coaching
  - To transition practice activities, some may need refresher training, coaching & feedback
- Staff Engagement
  - Perceptions & expectations
  - Confidence to change, embrace new practices

# ESoP Challenges - Vitalité

- Lack of regional clinical coordinator...
- Many vacant positions throughout all the sites

   Bilingual pharmacists
   rare commodity

#### **Bilingualism in Canada**



# Future Activities to Implement Expanded SoP

- Provincial WG
- Communication

   Pharmacists
- Communication
   Stakeholders
- Identify and fill gaps
  - Pharmacy staff
  - Stakeholders (nurses, physicians, others)



# Summary

- Pharmacist expanded scope of practice available with 2008 & 2014 legislation
- Hospital pharmacists are capable of taking on these roles & responsibilities for patients' drug therapy outcomes – prescribing & clinical tests are tools to this end
- Benefit to our patients should outweigh barriers to move forward in both RHAs

If I had an hour to solve a problem and my life depended on it, I would use the first 55 minutes determining the proper questions to ask.

Albert Einstein

# **Supplemental Slides**

#### **Evidence for Clinical Services**

- Bond & Raehl (2007)
  - Observational study of US hospitals' Medicare & Clinical Pharmacy Services 1998 databases:
    - Sample of 2.8 million Medicare admissions in 885 hospitals
  - Seven clinical pharmacy services were associated with reduced mortality rates (no. reduced deaths/hosp, mean±SD):
    - Drug-use evaluation: 5.37±4.29
    - Adverse drug reaction management: 23.30±19.38
    - Participation in cardiopulmonary resuscitation team: 45.84±31.92
    - In-service education: 18.38±13.96
    - Drug-protocol (medication) management: 29.87±22.41
    - Participation in medical rounds: 54.65±47.24
    - Admission drug histories: 107.78±87.60

#### **Evidence for Clinical Services**

- Kaboli et al. (2006)
  - Systematic review 1985-2005 incl 36 studies in ICU, med, surg & drug class-specific services
  - "Kaboli 5", improved patient outcomes shown for:
    - Participating on rounds with health care team
    - Interviewing patients
    - Reconciling medications
    - Providing patient discharge education
    - Providing post-discharge follow-up

*"Use of clinical pharmacists in the inpatient setting...resulted in improved quality, safety & efficiency of care."* 

#### **Evidence for Clinical Services**

- Chisholm-Burns MA et al. (2010)
  - Systematic review & meta analyses, 298 studies
  - 48% of all studies reported AHRQ level 1 outcomes
  - Therapeutic outcomes:
    - HbA1C, mean diff -1.8% (SD 0.5%, 95%Cl -2.7 to -0.9%)
    - LDLc, mean diff -6.3 mg/dL (SD 0.12 mg/dL, 95%CI -6.5 to -6.0 mg/dL); equiv to -0.163 mmol/L
    - BP, mean diff sBP -7.8 mmHg (SD 1.5 mmHg, 95%CI -9.7 to -5.8 mmHg)
  - Safety outcomes
    - 47% reduction in odds of adverse drug events (intervention vs comparison group, p=0.01)

#### **Evidence for Clinical Services**

- Makowsky M et al. (2009)
  - Prospective, controlled trial in 3 hospitals x 12 mos f/u
  - Adult inpts on 2 int med & 2 fam med units w/ primary diagnosis of CAD, CAP, COPD, HF or T2DM
  - Team-care-based (I) vs usual care RPh (C)
  - Results:
    - 56.4% of TC pts vs 45.3% of UC pts received care specified by QoC indicators
    - Lower 3-mo readmission rate (36 vs 45%) favouring TC w/ NNT=11 (pts to receive intervention to prevent 1 readmission)

"...team-based care including a clinical pharmacist, improved the overall quality of medication use and reduced rates of readmission."

#### **Evidence for Clinical Services**

- Gillespie U et al. (2009)
  - Prospective, RCT in single centre x 12 mos f/u
  - Adult inpts aged 80+ on 2 internal medicine units
  - RPh team-based (I) vs usual care (no ward RPh) (C)
  - Results favoured team-based RPh care:
    - Hosp readmission, 16% RRR (1.88 vs 2.24, 95%CI 0.72-0.99) → NNT=12 visits w/ intervention to prevent 1 future admission
    - ED visits, 47% RRR (0.35 vs 0.66, 95%CI 0.10-0.41)
    - Rx-related admission, 80% RRR (0.06 vs 0.32, 95%CI 0.10-0.41)

*"If implemented on a population basis, the addition of pharmacists to health care teams would lead to major reductions in morbidity (hospitalizations) and health care costs."*